Αρχική World News Giving Birth Before Age 20 Cuts Breast Risk By 50%, And A...

Giving Birth Before Age 20 Cuts Breast Risk By 50%, And A Drug May Be Able To Mimic That

Studies have shown that giving birth before the age of 20 can significantly reduce a woman’s risk of breast cancer. A Harvard University study of 17,000 women from countries with low, medium, and high breast cancer rates found that women who had a child before age 18 cut their breast cancer risk by 60% compared to women who had their first baby after age 35. Other studies have found that women cut their risk by 50%. It’s a significant form of protection.However, many women are now delaying childbirth later than ever to make room for personal accomplishments, careers, or because they simply can’t afford it. Other women are forgoing having biological children altogether.The natural protection that having a baby at a young age offers intrigued Jose and Irma Russo back in the 1970s. They were interested in determining the biological basis for this protection and worked together on that research for decades.Photo: Adobe Stock/Monkey Business
The link between breast cancer and reproduction isn’t simple, and a woman’s breast cancer risk relies on multiple factors. But the Russos discovered a lot over the course of their research.“We are very near to having the final answer and we worry that if we talk too much, it could fall apart,” Russo said. “But the idea is to produce the same changes as pregnancy — without pregnancy.”Photo: Adobe Stock/milosducatiThe Russos were both born in Argentina and then moved to the U.S. in 1971 and began a breast cancer research lab. Other researchers had theorized about the link between pregnancy and breast cancer risk, but the Russos found actual evidence, using cells and animal experiments to reach their conclusions.
They found that a woman’s mammary glands fully mature when full-term pregnancies trigger the growth of milk ducts. When the glands mature at a very young age, the chance of genetic damage to the cells that can be copied into new cells when they divide is significantly reduced.Photo: Adobe Stock/Cookie StudioIn the course of the their studies, the Russos found that hCG (human chorionic gonadotropin) prevented rats from developing breast cancer after they were exposed to cancer-causing elements. hCG is a hormone the body releases after implantation of the egg to maintain pregnancy. It’s also what most pregnancy tests measure to find out if a woman is pregnant or not.
They also identified 43 genes that are responsible for breast maturation. Some of these genes were also responsible for protecting a cell’s DNA from damage. They tightened up a cell’s nuclear DNA, something called “chromatin remodeling. The Russos found that pregnancy made the coiling in these genes even more compact, providing even more protection.Photo: Adobe Stock/tussikSadly, Irma passed away from ovarian cancer in 2013. Initially, Jose thought he wouldn’t be able to continue the work without her. But the next year, he began working with Herman Depypere, an obstetrician-gynecologist at Ghent University Hospital in Belgium.The clinical trial they led and their findings were published in the peer-reviewed journal Breast Cancer Research in 2019 and titled “Genomic Signature of Parity in the Breast of Premenopausal Women.”
Photo: Adobe Stock/WavebreakMicroThey gathered 35 childless women who were ages 18 to 30 and who had a BRCA1 or BRCA2 gene mutation. The women were injected with a fertility drug typically used to trigger ovulation, called Ovitrelle. It’s a type of synthetic hCG. The women were injected three times a week for three months. No side effects or other problems arose during those three months.This trial has helped push Russo one step closer to proving that the protection offered by pregnancy can be artificially triggered. However, even if the hCG causes the same changes in cells that actual pregnancy does, these women need to be followed for years to determine if it actually helped to prevent breast cancer. Additionally, larger trials that include women without any BRCA mutation would also need to be done.
Photo: Adobe Stock/RasiRusso thinks his research is very promising.“I would like this to be my legacy,” he said. “I am 77. I don’t know how long I will keep going. But the idea that we can confer protection without the necessity of childbirth is exciting. All we can do is learn from nature.”Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...